文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

正在参与肝纤维化的治疗靶点和有前途的治疗靶点:肝免疫微环境。

Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment.

机构信息

Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

出版信息

Front Immunol. 2023 Feb 16;14:1131588. doi: 10.3389/fimmu.2023.1131588. eCollection 2023.


DOI:10.3389/fimmu.2023.1131588
PMID:36875101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9978172/
Abstract

Hepatic fibrosis is often secondary to chronic inflammatory liver injury. During the development of hepatic fibrosis, the damaged hepatocytes and activated hepatic stellate cells (HSCs) caused by the pathogenic injury could secrete a variety of cytokines and chemokines, which will chemotactic innate and adaptive immune cells of liver tissue and peripheral circulation infiltrating into the injury site, mediating the immune response against injury and promoting tissue reparation. However, the continuous release of persistent injurious stimulus-induced inflammatory cytokines will promote HSCs-mediated fibrous tissue hyperproliferation and excessive repair, which will cause hepatic fibrosis development and progression to cirrhosis even liver cancer. And the activated HSCs can secrete various cytokines and chemokines, which directly interact with immune cells and actively participate in liver disease progression. Therefore, analyzing the changes in local immune homeostasis caused by immune response under different pathological states will greatly enrich our understanding of liver diseases' reversal, chronicity, progression, and even deterioration of liver cancer. In this review, we summarized the critical components of the hepatic immune microenvironment (HIME), different sub-type immune cells, and their released cytokines, according to their effect on the development of progression of hepatic fibrosis. And we also reviewed and analyzed the specific changes and the related mechanisms of the immune microenvironment in different chronic liver diseases.Moreover, we retrospectively analyzed whether the progression of hepatic fibrosis could be alleviated by modulating the HIME.We aimed to elucidate the pathogenesis of hepatic fibrosis and provide the possibility for exploring the therapeutic targets for hepatic fibrosis.

摘要

肝纤维化通常是慢性炎症性肝损伤的结果。在肝纤维化的发展过程中,致病损伤引起的受损肝细胞和活化的肝星状细胞(HSCs)可分泌多种细胞因子和趋化因子,趋化肝组织和外周循环中的固有和适应性免疫细胞浸润到损伤部位,介导针对损伤的免疫反应并促进组织修复。然而,持续释放持续性损伤刺激诱导的炎症细胞因子会促进 HSCs 介导的纤维组织过度增殖和过度修复,从而导致肝纤维化的发展和进展,甚至导致肝硬化和肝癌。活化的 HSCs 可分泌各种细胞因子和趋化因子,直接与免疫细胞相互作用,并积极参与肝病的进展。因此,分析不同病理状态下免疫反应引起的局部免疫稳态变化将极大地丰富我们对肝病逆转、慢性化、进展甚至肝癌恶化的认识。在这篇综述中,我们根据它们对肝纤维化发展和进展的影响,总结了肝免疫微环境(HIME)的关键组成部分、不同亚群免疫细胞及其释放的细胞因子。我们还回顾和分析了不同慢性肝病中免疫微环境的具体变化及其相关机制。此外,我们还回顾性分析了调节 HIME 是否可以减轻肝纤维化的进展。我们旨在阐明肝纤维化的发病机制,并为探索肝纤维化的治疗靶点提供可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/f4275b2b0c9b/fimmu-14-1131588-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/8a7a6c9e55a0/fimmu-14-1131588-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/5c3f058d6940/fimmu-14-1131588-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/d5cd9d7508d1/fimmu-14-1131588-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/f4275b2b0c9b/fimmu-14-1131588-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/8a7a6c9e55a0/fimmu-14-1131588-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/5c3f058d6940/fimmu-14-1131588-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/d5cd9d7508d1/fimmu-14-1131588-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7144/9978172/f4275b2b0c9b/fimmu-14-1131588-g004.jpg

相似文献

[1]
Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment.

Front Immunol. 2023

[2]
Cooperation of liver cells in health and disease.

Adv Anat Embryol Cell Biol. 2001

[3]
Hepatic Stellate Cell Modulates the Immune Microenvironment in the Progression of Hepatocellular Carcinoma.

Int J Mol Sci. 2022-9-15

[4]
Cross-talk between hepatic stellate cells and T lymphocytes in liver fibrosis.

Hepatobiliary Pancreat Dis Int. 2021-6

[5]
Intercellular communication among liver cells in the perisinusoidal space of the injured liver: Pathophysiology and therapeutic directions.

J Cell Physiol. 2023-1

[6]
Exosomes in liver fibrosis: The role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications.

Front Immunol. 2023

[7]
Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis.

J Cell Physiol. 2022-1

[8]
Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Drugs. 2021-3

[9]
Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.

Acta Biomater. 2022-10-15

[10]
Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice.

J Hepatol. 2017-7-26

引用本文的文献

[1]
The AURKA-Selective Inhibitor Alisertib Attenuates Doxorubicin-Induced Hepatotoxicity in Mice via Modulation of IL-17A/NF-κB and STAT3 Signaling Pathways.

Pharmaceuticals (Basel). 2025-8-14

[2]
Nanomedicines in the Treatment of Liver Fibrosis: A Review.

Int J Nanomedicine. 2025-8-5

[3]
Protective Effect of Hordenine on Concanavalin A-Induced Hepatic Injury.

J Inflamm Res. 2025-7-23

[4]
Role of mitogens in normal and pathological liver regeneration.

Hepatol Commun. 2025-4-30

[5]
The effect and application of adiponectin in hepatic fibrosis.

Gastroenterol Rep (Oxf). 2024-12-30

[6]
Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma.

Transl Oncol. 2024-10

[7]
A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma.

Phenomics. 2023-12-8

本文引用的文献

[1]
Upregulation of GLT25D1 in Hepatic Stellate Cells Promotes Liver Fibrosis via the TGF-β1/SMAD3 Pathway and .

J Clin Transl Hepatol. 2023-2-28

[2]
Si-Wu-Tang ameliorates bile duct ligation-induced liver fibrosis via modulating immune environment.

Biomed Pharmacother. 2022-11

[3]
Hepatic Stellate Cell Modulates the Immune Microenvironment in the Progression of Hepatocellular Carcinoma.

Int J Mol Sci. 2022-9-15

[4]
Aberrant peribiliary gland niche exacerbates fibrosis in primary sclerosing cholangitis and a potential therapeutic strategy.

Biomed Pharmacother. 2022-9

[5]
Myeloid cells in alcoholic liver diseases: Mechanism and prospect.

Front Immunol. 2022

[6]
A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice.

Ann Med. 2022-12

[7]
Viral hepatitis elimination: a challenge, but within reach.

Lancet. 2022-7-23

[8]
Comparing Mouse and Human Tissue-Resident γδ T Cells.

Front Immunol. 2022

[9]
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.

Int J Mol Sci. 2022-6-15

[10]
Macrophages as key regulators of liver health and disease.

Int Rev Cell Mol Biol. 2022

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索